A potentially promising combination therapeutic strategy is combining t-CDK inhibitors with therapies that target sex hormone signalling axes (i.e. AR-targeted therapies in prostate cancer and equivalent therapies targeting the estrogen receptor in breast cancer) (Fig. 4). The gene discussed is AR; the disease is prostate carcinoma.